BACKGROUND: Single-patient trials (SPTs) are randomized, often multiple-crossover trials where patients serve as their own control to determine their appropriate treatment. Historically, SPTs have been individually customized, requiring significant time and cost for execution. The patient's progress is tracked and evaluated in a blinded, multiple-crossover design comparing different therapies. Standardized, cost-efficient SPTs could help avoid (a) inappropriate extrapolation of the average-group outcomes from parallel, clinical trials to community-practice patients and (b) wasteful prescribing of high-cost drugs. Aggregate SPT results can also provide new data on appropriate drug prescribing in subpopulations.
O R I G I N A L R E S E A R C H
astroesophageal reflux disease (GERD) is the retrograde movement of stomach contents into the esophagus. 1 More than 60 million American adults experience GERD and heartburn at least once a month and about 25 million adults experience heartburn daily. 2 Erosive esophagitis (EE) is a part of the spectrum of GERD, but not all patients with GERD experience EE. 3 The only Food and Drug Administration (FDA)-approved, chronic indication for GERD sufferers is maintenance of healing of EE.
In practice, the presence and healing of EE may not be objectively confirmed. 4 Endoscopy is currently the most appropriate test to document the mucosal damage associated with EE due to GERD. 4 However, in a managed care environment, this procedure is generally not performed when patients initially present with symptoms. 4 Instead, patients are often treated symptomatically. GERD is a chronic condition, and patients often experience symptomatic relapses. Many patients with GERD may require pharmacologic maintenance regimens to prevent symptoms. 5 Patients with less severe disease may not require maintenance therapy at all or may be successfully treated with intermittent treatment to control symptomatic recurrences.
GERD is commonly treated with acid-suppressing agents such as proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H 2 RAs). Omeprazole, a PPI, and ranitidine hydrochloride (ranitidine), an H 2 RA, are both FDA-approved for short-term, symptomatic relief of GERD with or without EE. In order to obtain FDA approval to market these drugs in the United States for these indications, the sponsoring companies were required to demonstrate the products' efficacy and safety through adequate and well-controlled clinical trials. However, prescribing physicians cannot use these data to reliably predict how their individual patients will respond to these specific drugs.
For example, in the clinical trials submitted to the FDA in support of omeprazole for the treatment of GERD, 48% of patients experienced complete relief after treatment with omeprazole 20 mg daily compared to 14% of those treated with a placebo. 6 While this difference is statistically significant and was the basis for FDA approval of this drug for GERD, 52% of patients still experienced GERD symptoms that were not relieved by omeprazole treatment. Assuming that a placebo response occurs with equal frequency in active and placebo groups due to randomization, subtracting the placebo response rate (14%) from the omeprazole rate (48%) provides an estimated true drug response rate of only 34%. In fact, 22% of
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omeprazole-treated patients still reported heartburn on 5 to 7 days out of the last study week.
Single-patient drug trials (SPTs) have been accepted by both patients and physicians as a useful tool for guiding treatment decisions by evaluating drug effectiveness and tolerability in individual patients who serve as their own controls. 7 These trials are only useful for management of chronic diseases in which therapy leads to temporary alleviation of manifestations rather than lasting modification of a disease process. Within the context of the hierarchy for evidence-based study designs, SPTs deliver the highest strength-of-evidence for making individual patient treatment decisions. 8 According to the Evidence-Based Medicine Working Group (American Medical Association), SPTs are superior to group-randomized trials, observational studies, and physiologic studies for targeting individual-patient treatment. 8 The weakest data in the hierarchy are unsystematic, clinical observations; unfortunately, these uncontrolled observations are routinely relied upon as the basis for treatment decisions. 8 In addition to providing treatment guidance for individual patients, SPT results can be aggregated to provide inferences regarding drug effects in populations/subpopulations. 7 The aggregate database can also be applied to each individual patient to enhance statistical power to detect differences, permitting greater certainty of each individual' s prognosis. 9, 10 Historically, SPTs have been individually customized, thus requiring a considerable effort for design, conduct, and analysis. Not surprisingly, the time and cost of such individually customized trials have severely limited their use. This paper reports the results of a standardized methodology that can be used routinely in clinical practice to optimize treatment decisions on an individual-patient basis for GERD.
The present effort is directed at the development of uniform, commercially available SPT kits, thereby creating economies-ofscale to support evidence-based treatment decisions for patients requiring GERD maintenance therapy. To scale-up this technology for widespread community use in medical practice, it was necessary to define an approach for validation of test kits based upon standards established for other forms of clinical research, such as group randomized, controlled trials. 11 It was necessary to demonstrate that (a) the components are user-friendly, i.e., able to capture the required data with minimal supervision of patients, and (b) the methods have sufficient sensitivity and specificity with respect to the detection of clinically relevant differences between the compared drug treatments.
For this study, validation was facilitated by the fact that recent U.S. FDA approvals of drugs for GERD and for maintenance of healing of EE were based on pivotal trials in which many of the primary efficacy endpoints were obtained from diaries completed by patients. Therefore, it was possible to base the test kits on a "gold standard" 11 : the diary questions used in a modern U.S. FDA approval. To complete the SPT validation, it had to be shown that those test instruments previously validated in new-drug applications are feasible to administer with minimal support by the physician' s office, reproducible when used in an SPT design, and able to statistically discriminate relevant clinical information when used in SPTs. 12 The divergence in cost of the 2 comparator drugs in this category at the time of this writing is an example of the potential financial advantage SPTs can offer. The generic availability of all H 2 RAs, including ranitidine, cimetidine, nizatidine, and famotidine, has made these drugs relatively inexpensive in comparison to the (currently) brand-only PPIs. Therefore, SPTs could decrease the cost of health care on those occasions when therapeutic substitution with the less expensive agent is suggested from test results. When targeted for use by appropriate patients, SPT methodology would make the therapeutic substitution obvious to the prescriber by providing reliable statistical data in place of unblinded and uncontrolled anecdotal patient reports. If head-to-head comparisons between PPIs and H 2 RAs can create a substantial opportunity for evidence-based substitution, the substitution rates may be even greater for comparisons between 2 PPIs, given the greater pharmacologic similarity between the compared drug treatments. Higher switch rates could occur, for example, when a generic omeprazole oral dosage form is marketed and compared to a brand-name PPI.
The purpose of this study was 2-fold: (1) to validate an SPT methodology for acid-suppressing medications, such as PPIs and H 2 RAs, in the treatment of patients with a clinical or empirical diagnosis of GERD not proven through 24-hour pH monitoring or barium swallows, and (2) to validate a method for substituting a less expensive agent, such as an H 2 RA, with an equivalent or better effectiveness/safety profile.
Unlike trial-and-error, financially driven, step-down approaches, the GERD SPT was designed to provide health care professionals with objective data based on each patient' s individual response to treatment, thus allowing the most appropriate, safe, and effective therapy to be individually tailored to meet each patient' s treatment goals (i.e., relief of symptoms). The test kit was designed for effective execution by minimally deviating from ordinary medical practice. The physicians need only write a simple prescription for a specific protocol, as they would for a laboratory test. They would then receive a report with the essential results boldly highlighted for rapid interpretation. By adding controlled evidence to decision making rather than relying on unsystematic clinical observation, the physician can have an opportunity to reduce risk to the patient of GERD sequelae, such as Barrett' s esophagus and esophageal cancer. The pharmacy-based, drug-therapy-management company that produced the SPT is structured to provide patient counseling and customer service and serves as an impartial, independent, unbiased provider of SPT testing services.
■■ Materials and Methods
For the purpose of validation prior to commercial use of test kits for GERD, 32 patients were enrolled in SPTs. Each was a double-blind, randomized, 3 paired-period, multiple-crossover trial of 84 days duration comparing omeprazole to ranitidine. Patients served as their own control to determine the relative effectiveness and adverse event profile for the 2 drugs in each individual. 7 In all trials, omeprazole 20 mg taken in the morning and placebo in the evening were compared to ranitidine 150 mg taken in the morning and evening, each taken for a 14-day course. Therefore, all patients experienced a twice-daily dosing regimen. Patients were instructed to take the morning dose before a meal, and the evening dose approximately 12 hours later. The doses selected were based on the usual recommended adult dose according to product labeling.
Selection for evaluation of a 14-day period for each leg was based on the pharmacologic profile of omeprazole, a long-acting PPI. The inhibition of gastric acid secretion by omeprazole persists for up to 72 hours and increases, with continued use reaching a plateau after about 4 days of therapy. Following discontinuation of omeprazole, gastric acid secretion returns to baseline over a 3-to 5-day period. 13 This would theoretically provide for a substantial time period that is minimally affected by carryover effects.
Published data from SPTs suggest that 3 pairs of periods (6 treatment periods) can provide sufficient power to distinguish between active drug and placebo for a drug known to be safe and effective in group trials.
14 Since there were no earlier published SPTs for GERD in the literature, we elected to conduct 30 trials to obtain sufficiently precise estimates of variance so that the power of various potential kit configurations to detect differences in the key variables could be evaluated. The purpose of each individual test was to generate data on the comparative effectiveness and adverse event profile of the 2 acid-suppressing agents to guide future prescribing for each individual patient.
For the ordinal variable, Patient Global Score, significance was assessed for each SPT by applying aggregate single-patient data from all patients to enhance statistical power. 9, 10 This was analyzed with a modified paired 2-tailed t test at α=0.10, utilizing a pooled variance estimate based on a hierarchical linear model incorporating the data from all patients. 15 Individual GERD symptoms were analyzed on the basis of percentage of symptom-free days using a 2-tailed χ 2 test 16 at α=0.10 (see Discussion for further explanation). There was an a priori assumption that data collected late (on days 8 to 14) during the study leg can be weighted more heavily, or early data (on days 1 to 7) can be excluded to enhance discrimination, as warranted by sensitivity analysis of aggregate data. This could correct for carryover effects from the prior study leg, as appropriate, and serve as a surrogate washout period between the compared drug treatments. 17 The observations for days 1 through 4 of each 14-day treatment period were thereby excluded from the analysis in order to minimize the potential for carryover effects from the previous treatment. There was approximately 75% power to detect a 20% difference in each effectiveness measure.
All adverse events were captured in a manner consistent with the FDA MEDWATCH program, 18 and were measured and compared based on the percentage of study days in which the patient reported specific adverse events. Incidences of adverse events were compared via 2-tailed Fisher' s Exact tests 19 at α=0.10. All available data points were included in the analysis.
The power to detect a 30% difference in adverse event incidence was greater than 80%.
Patients were recruited and follow-up was performed by Radiant Research, West Palm Beach, Florida. Recruitment began on January 22, 2001 , and the trials were completed on August 17, 2001. The database was closed for final analysis on November 21, 2001 . Because subject participation would directly benefit a commercial sponsor, the protocol was approved by an investigational review board, and subjects were required to provide written, informed consent.
A computer-generated randomization schedule was provided by the sponsor. Individual test kits were consecutively numbered in advance of patient enrollment, and the randomization key was not provided to physicians, the investigational site, or participants. Patients were enrolled by the study coordinator and assigned to a test kit in the order of presentation to the site. The randomization was revealed to the physician, investigational site, and participant only after all of the individual' s data had been collected and analyzed. All drug doses were blinded using Gallipot dark green #2 capsules, with lactose as filler. Drug doses were provided in consumer-friendly packaging, including an outer box bearing a brief description of the test kit and 12 envelopes each containing a 7-day, compliance-labeled blister card identifying AM and PM doses, a diary, and instructions. Patients were instructed to take their morning dose after a meal, and their evening dose approximately 12 hours later. Omeprazole was taken in the morning and a placebo in the evening. Ranitidine was taken both in the morning and evening.
Male or female patients 18 years or older in otherwise good general health and with chronic GERD were recruited to participate in the study. All patients were chronic users of acid-suppressing medications. The investigating physician relied on symptom history along with chronic use of acid-suppressing medications to identify patients who would potentially benefit from an SPT. At the first study visit (Screening Visit/Day 0), each patient was asked to confirm the presence of GERD symptoms. Patients with self-reported symptoms were evaluated by the investigator for confirmation of the diagnosis and a review of the inclusion and exclusion criteria. Investigators also confirmed that they would choose to prescribe the SPT to the patient and that, in their medical opinion, the patient would benefit directly from the trial.
Patients were to be excluded if (a) the investigator considered the patient to have medical conditions that would cause the patient to be placed at risk by trial participation, such as pregnancy (due to multiple-drug exposures) or renal failure; (b) the patient had known hypersensitivity to omeprazole or ranitidine or any components of the formulations; (c) the patient was unable or unwilling to comply with the protocol or was unable to comprehend and satisfactorily use the measurement scales as determined by the investigator or designee at screening; (d) the patient was on other medications that have known drug interactions with PPIs or H 2 RAs; (e) the patient was not willing to abstain from routine stomach remedies (i.e., PPIs, H 2 RAs, antacids, alginic acid preparations, bismuth preparations, prokinetics, sucralfate) other than the study drug, during the study; (f) the patient was initiating or changing a regimen including immunotherapy, anticholinergics, or prokinetics during the course of the study or was on maintenance therapy for less than one month; (g) the patient was treated with immunosuppressives, radiation therapy, PPIs, H 2 RAs, antacids, alginic acid preparations, bismuth preparations, anticholinergics, prokinetics, or sucralfate over the past 3 months and/or required such therapy during the course of the study; (h) the patient had a history of abuse of alcohol or any other recreational or prescription drug within the year prior to the study; or (i) the patient was using antidepressant pharmacotherapy (due to anticholinergic effects). A patient would be excluded had they been on methotrexate, for example, and had the potential for drug-induced esophagitis. The use of rescue medications was allowed during the study. All patients were chronic users of acid-suppressing medications by history.
Three recruitment methods were employed concurrently: advertising with telephone screening, physician referrals, and outbound calls to potential GERD sufferers who participated in previously conducted clinical trials. Sixty-six potential subjects responded to advertising and were screened during in-bound telephone calls at a call center prior to the first visit. Of these, only one presented for an initial visit and was entered. The remaining 65 of these call center subjects were excluded during the telephone interview because they were not able or willing to comply with the protocol requirements. There were no other reported reasons for exclusion, and all subjects were entered at their initial visit. Thirteen subjects were referred by their physician. Eighteen subjects were recruited via an outbound telephone call because they had participated in another clinical trial and were known to have had GERD.
Patients responded to 9 distinct effectiveness questions on a daily basis and to 2 distinct effectiveness questions on a weekly basis. This represents a superset of the questions ordinarily asked of patients in clinical trials for regulatory drug approval and was intended to provide insight into possible optimization by targeting primary endpoints for a future commercial version of this SPT kit.
Effectiveness analyses were based on patient daily evaluations of the following symptoms: heartburn, regurgitation, difficulty swallowing, epigastric (stomach) pain, and nausea. The severity of each of these symptoms was rated using a 4-point scale: 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The patients were also asked to respond either yes or no to the following questions every day: (1) Have you experienced a rising, spreading uncomfortable feeling behind your breastbone within the last 24 hours? (2) Was this feeling combined with a burning sensation in your chest? (3) Did you have these symptoms during the last 24 hours? and (4) Did you use anything else (besides study medication) for these symptoms? Question 4 was asked to determine if "rescue" medications were used. In addition, frequency of symptoms was recorded weekly using the following scale: none, 1 day, 2 to 4 days, 5 to 6 days, or 7 days. The patient' s "most bothersome symptom" was recorded at baseline. The criterion variable for analysis of each question was percent of symptom-free days (or rescue-free days for question 4). An additional effectiveness variable was the weekly patient global score, a single-item question: "How would you rate this drug for the prevention of your reflux symptoms?" This was rated on a scale of 1 (poor) to 10 (excellent).
Each patient recorded all adverse events experienced during the trial. Patients were asked daily about typical adverse events expected to occur frequently, based on product labeling for GERD medications. 13 These included headache, dizziness, rash, diarrhea, lower abdominal pain, nausea, vomiting, constipation, weakness, back pain, upper respiratory infection, cough, bloating, and excess gas. Because patients served as their own control and the compared drug treatments were administered on a random schedule, no bias was introduced by soliciting for adverse events and statistically comparing the frequency of adverse events from one drug to the other.
At the end of the study, the patients were also asked to perform a quality evaluation of the test kit itself that involved providing a "liking/disliking" score for the test kit and all of its components, including ease of use and suggestions for improvement. Patients were offered a new prescription for treatment based on the guidance provided using the patient' s results from the SPT.
■■ Results
A total of 32 subjects entered the study. Of these 32 subjects, 27 subjects (84%) were evaluable for the effectiveness analysis. Five subjects discontinued the study prior to providing sufficient data for a meaningful analysis. Three patients (102, 111, and 130) were discontinued due to reported lack of effectiveness (all were taking ranitidine). The data available from these ranitidine patients were insufficient for any conclusions to be made regarding relative drug effectiveness and safety and/or subsequent disease management. One patient (117) was lost to follow-up while taking omeprazole, and one (129) was lost to follow-up with no treatment information. The returned compliance-packaged study medications were generally consistent with data recorded in patient diaries.
Of the 27 evaluable subjects, 19 (70%) were female and 8 (30%) were male. Twenty-five (92%) of the subjects were white, 1 (4%) was black, and 1 (4%) was Hispanic. The mean age was 62 years (SD±13.62), ranging from 35 to 84 years. The mean weight was 177 pounds (SD±35.41), ranging from 100 to 242 pounds. Nineteen subjects (70%) were classified as obese (more than 20% over ideal body weight). The mean height was 66 inches (SD±2.88), ranging from 61 to 71 inches. The most bothersome symptom for each patient as reported by the 27 patients was as follows: 17 (63%) heartburn, 7 (26%) regurgitation, and 3 (11%) difficulty swallowing. A summary of the demographic data and baseline symptom scores for the subjects is included in Table 1 . The age and weight distributions are consistent with the reported association of higher age and weight with GERD. 20, 21 The medical history of the subjects included the following concomitant conditions: dyslipidemia-12 subjects, hypertension-12 subjects, arthritis (i.e., osteoarthritis, gout)-5 subjects, asthma-2 subjects, diabetes mellitus-2 subjects, glaucoma-2 subjects, migraines-2 subjects, chronic obstructive pulmonary disease-1 subject, and hypothyroidism-1 subject. Five subjects (107, 108, 109, 119, 120) had irritable bowel syndrome. Four subjects (106, 108, 109, 132) had erosive esophagitis. No trends were discernible for differences in adverse-event profiles or effectiveness for these population subgroups. OME superior: use OME OME superior: use OME OME superior: use OME OME superior: use OME OME superior: use OME OME superior: use OME RAN superior: use RAN OME superior: use OME Neither agent can be recommended, both caused adverse events; may retest using different agents RAN superior: use RAN** OME superior: use OME Neither agent can be recommended; may retest using different agents † † Parity performance: use RAN OME superior: use OME OME superior: use OME ‡ ‡ Table 2 shows the statistically significant findings for all evaluable SPTs. All of the patients had been using an acid-suppressing medication prior to starting the study. Of 27 evaluable tests, only 14 (52%) showed significant superiority for omeprazole over ranitidine. Eleven patients (41%) had superior or parity response to ranitidine versus omeprazole, indicating that the less expensive agent (ranitidine) was the appropriate treatment. When no statistically significant differences were found between drugs for effectiveness measures and adverse events, or findings were equivocal, this was classified as parity performance, and guidance for future pharmacotherapy was determined by which drug treatment was less costly. In 2 of 27 trials (7%), neither agent could be recommended due to adverse events for both, and, therefore, the prescriber could appropriately conclude that the patient should cease drug treatment and/or seek other treatment modalities/SPTs. Given the significant cost difference between these 2 products, 48% of patients could be either placed on the less expensive agent or were shown to be poor candidates for either the expensive or inexpensive drug (90% confidence interval: 32% to 64%). That is to say, in only 14 of 27 trials (52%) was omeprazole found to be the agent of choice for an individual patient presenting as a chronic user of acid-suppressing drugs. Seven of 27 patients (101, 107, 108, 122, 123, 125, 132) were taking an H 2 RA just prior to the study. Of these, 3 showed superiority for ranitidine, 2 showed parity performance, and 2 showed superiority for omeprazole.
* Effectiveness endpoints measured include heartburn, regurgitation, difficulty swallowing (diff. swallow), stomach pain, nausea, uncomfortable feeling behind the breastbone (breastbone), burning sensation in the chest (burning chest), reported symptoms during the last 24 hours of each treatment period (last 24 hours), less frequent use of rescue medications (rescue meds), and patient global rating (pt. global). † Omeprazole (OME) shows superiority over ranitidine hydrochloride (RAN) for these effectiveness endpoints. ‡ Ranitidine hydrochloride (RAN) shows superiority over omeprazole (OME) for these effectiveness endpoints. § Omeprazole (OME) has a higher incidence than ranitidine hydrochloride (RAN) for these adverse events (AEs). || Ranitidine hydrochloride (RAN) has a higher incidence than omeprazole (OME) for these adverse events (AEs
This sample size (7) is too small to subject to statistical analysis with regard to potential step-up therapeutic substitution rates from ranitidine to omeprazole. When these 7 patients were deleted from the analysis, the step-down substitution rate from the PPI to the H 2 RA, combined with the drug therapy discontinuation rate, was 40% (90% confidence interval: 22% to 68%). For the 20 prior PPI users, omeprazole was superior in 12 (approximately 60%), ranitidine in 4 (20%), 2 (10%) showed parity performance, and for 2 (10%), neither drug was recommended.
Overall, 21 of 27 trials (78%) identified one drug or the other as superior, 4 of 27 (15%) showed no difference between drugs (parity performance), and 2 of 27 (7%) showed that neither drug was appropriate. Of the 11 of 27 trials (41%) indicating that ranitidine was the preferred treatment, 7 (26%) showed superiority for ranitidine over omeprazole. In 2 of these trials, ranitidine was shown to be superior despite the fact that there was no significant difference in effectiveness between omeprazole and ranitidine; these patients experienced a significantly higher incidence of adverse events in association with the use of omeprazole (rash and constipation in one patient, headache and lower abdominal pain in another patient). The remaining 4 of the 11 (ranitidine-preferred) trials showed parity performance as a basis for ranitidine substitution because it is the less expensive agent. Two of 27 trials (7%, patients 124 and 127) presented instances where neither drug could be recommended because both agents caused significant adverse events. For patient 127, this occurred despite having a superior response in effectiveness to ranitidine. Where neither drug can be recommended, the prescribing physician may choose to stop all treatment, use a nondrug, alternative treatment, or retest to compare 2 other drug treatments in an SPT.
As shown in Table 2 , 9 subjects experienced a significantly higher incidence of specific adverse events in association with the use of omeprazole as compared with ranitidine, and 12 subjects experienced a significantly higher incidence of specific adverse events in association with the use of ranitidine as compared with omeprazole. The use of a multiple-crossover design served as an a priori decision to rechallenge and thereby established the relationship between the drug and the adverse event, thus permitting clear discrimination of which drug caused a given adverse event.
The patients were also asked to complete a kit-acceptability questionnaire. Ninety-six percent of the patients reported that they understood the diary questions, and all understood the dosing instructions as well as the purpose of the test kit. All wanted to see their test results. Sixty-one percent of the patients felt that the diary questionnaire was of appropriate length. Of the 10 patients who had previously taken an in-home test, 8 preferred this kit. Sixty-seven percent of the patients said that they would prefer to first use the kit before going on a chronic medication for GERD. The responses also confirmed that the clinical supplies were successfully blinded. An analysis of baseline symptom scores for heartburn and regurgitation did not suggest an association between disease severity and the patient' s preference for use of the kit (P=1.00 and P=0.66, respectively). Also, taking the patient global score, averaged over all treatment periods, as a measure of a patient' s well-being during the trial, there was no discernible relationship to global scores when comparing those patients who expressed preference for taking the test and those who did not (P=0.89). Therefore, patient ratings regarding the kit appeared to be independent of their disease state.
■■ Discussion
The GERD SPT kit has completed validation. It was feasible to administer, and it could statistically discriminate valuable prognostic information using "gold standard" test instruments previously validated in large-scale parallel trials as well as discriminate for adverse events. On this basis, it can be recommended for routine use in community practice. The need for validated and reliable SPT methods in gastrointestinal pharmacology has been a topic of recent evaluation. 22 PPIs and H 2 RAs both have excellent safety records and are considered to be extremely well-tolerated. 5 However, in this study, 9 subjects experienced a significantly higher incidence of specific adverse events in association with the use of omeprazole as compared with ranitidine, and 12 subjects experienced a significantly higher incidence of specific adverse events in association with the use of ranitidine as compared with omeprazole. While the overall perception of these classes of drugs is that they are generally safe, the impaired quality of life of the patient who experiences an adverse event, even a mild to moderate one, may not be appropriately matched to the drug' s benefit. A clear advantage of this SPT methodology is the unique ability to definitively detect differences not only in effectiveness but also in adverse events for individual patients by virtue of a priori rechallenge.
These results indicate that for patients currently on PPIs, it is possible to therapeutically substitute with H 2 RAs (or discontinue therapy) in approximately 4 of 10 patients in clinical practice using this evidence-based approach. These SPT outcomes cannot be inferred from group, parallel trial data in part because group study designs rarely compare therapeutic alternatives head-to-head; they are usually conducted for the purpose of drug approval, requiring superiority to placebo only. When parallel, head-to-head comparisons of 2 active agents are available, discrimination of parity or superior performance is never possible for individual patients because they are exposed to a single drug/dose during the trial. Stated differently, in a group trial, there is no crossover comparison between drugs in the same individual to permit assessment of relative performance in that individual.
The results of this study show that the test kits can be used successfully to assist in determining the more appropriate drug for each patient. Only those patients who actually respond better to omeprazole need be treated with this considerably more expensive drug (at the time of this writing). The cost for a 30-day supply of Prilosec (omeprazole, 20 mg QD) is $62.37, using the Federal Supply Schedule. 23 In contrast, the Federal Supply Schedule cost for a 30-day supply of generic ranitidine (150 mg BID) is $2.50. 23 This is equivalent to an annual cost savings of $718.44 for each patient treated with ranitidine rather than with omeprazole.
It can be projected that payers in the United States will spend more than $10 billion this year on prescriptions for PPIs. The use of SPTs to optimize outcomes in a step-down therapy approach for GERD may have a secondary, but nevertheless profound, impact on health care costs. It is plausible that the substitution rate reported in the current work (via a series of individual tests for validation purposes) can be maintained or improved upon through formulary controls in actual health care practice.
The rate for step-down from a brand-name PPI to a generic PPI can be expected to be much higher than from a PPI to an H 2 RA because drugs in the same class can be expected to have a much higher incidence of parity performance. Speculatively, a step-down rate of 75% or greater can be realized where clinical and molecular differentiation between drugs are modest.
Therapeutic substitution performed by a prescriber may occur in 2 scenarios. The first scenario is a potentially biased anecdotal patient report of minimal or suboptimal treatment with the current therapy. Here, the prescriber may change medications only to find out that the replacement medication is less effective or has worse side effects than the initial one. The second scenario, which seems to be of greater consequence in recent times, is a change to satisfy a restriction or to reduce a copay based on a managed care formulary. In this case, the prescriber is forced to make substitutions based on financial savings, which may benefit the patient, payer, or both, but not necessarily based on outcomes.
SPTs can remedy the deficiencies of these approaches to treatment by providing unbiased, within-patient, statistical data to help the prescriber optimize therapy, in this case, at a rate of 78%, where one drug or the other is shown to be superior. Moreover, assuming that therapeutic substitution with a less expensive agent and/or drug discontinuation will occur at a rate of approximately 40%, managed care organizations (MCOs) can advantageously modify their current formularies to include evidence-based SPT methods in order to insure that patients get what they objectively need. Such a change, if mandated through "National Drug Code (NDC) lockouts" of brand-name drugs (unless initially dispensed in an SPT), can be expected to result in greatly improved effectiveness/safety outcomes, greater patient satisfaction with the physician and plan, less bureaucracy for the physician by eliminating prior-authorization paperwork, and reduced drug expense for the payer.
The execution of a GERD SPT program in an MCO can be particularly appropriate once there is widespread availability of generic omeprazole. Rebates paid by manufacturers of brandname PPIs to obtain formulary access and preferred formulary positions at pharmacy benefit managers (PBMs) may account for a significant portion of a PBM' s total net profits and may discourage PBMs from aggressive promotion of generic therapeutic alternatives to brand PPIs. A GERD SPT program could be used to determine the most cost-effective drug therapies for individual patients suffering from GERD or EE.
To replace products losing patent protection, pharmaceutical companies periodically introduce new chemical entities, an isomer (or other new form of an older drug), more convenient dosing regimens, and drug combinations. These are heavily marketed to doctors and patients as the latest advancement in care, limiting the growth of generic drug market share. For example, the manufacturer of Prilosec launched Nexium (esomeprazole magnesium) and engaged in an advertising and marketing strategy to convert Prilosec users to Nexium before patent expiry and generic availability of omeprazole.
In this environment, SPT kits can provide significant value to patients and payers alike. When there are no effectiveness or side-effect differences between the 2 drugs as determined by a fully validated SPT, it is appropriate to prescribe the more established, predictable drug. As a step-down therapy approach, an SPT consisting of 2 PPIs can be used to switch patients back to the less expensive therapy. Thus, patients use a drug that has a more established safety profile, and payers can design a formulary to objectively and independently get patients on the drug they need. Although rebates may influence the selection of particular drugs as step-down candidates, this does not limit the ability of SPTs to appropriately reduce utilization and costs of step-down candidates once they are targeted, in consideration of existing contracts and financial projections.
Our discussions with physicians and MCOs indicate that the prior-authorization systems to restrict expensive brand-name drug use do not work satisfactorily for either party. Doctors resent dealing with restrictions and manage to overcome this hurdle. MCOs, therefore, experience growing usage of new, expensive drugs.
A health plan formulary can eliminate prior-authorization restrictions by instead requiring SPTs for short-term trial of 2 substitutable, chronic care drugs as a condition for refill. Patients could experience improved outcomes and fewer adverse events. Physicians could prescribe any brand-name drug they deem appropriate. Payers could avoid paying for inappropriate refills, or, alternatively, collect higher copayments on brand-name drugs that perform statistically no better or worse than the more established generic substitute. The requirement can be enforced through NDC lockouts, which only permit initial brand-name drug usage in an SPT kit. Once patients' data demonstrate that the brand-name drug is superior for them, the NDC lockout is lifted for that patient. Insurers and employers are currently considering such a formulary design. Indemnity health plans may be particularly well suited to this approach.
Each SPT result may represent a snapshot in time because disease and drug activities can wax and wane dynamically and interactively over time. Periodic retesting of comparative effectiveness and safety between 2 active drugs can be used to further optimize chronic disease treatment. Also, it may be appropriate to periodically conduct controlled "drug holidays" by comparing an active drug to a placebo. Comparisons of different doses of the same drug could also serve to optimize outcomes.
It is appropriate that different statistical criteria be applied to group trials conducted for drug approval and SPTs conducted to assess appropriate individual treatment. For group trials, the greater risk is to find a difference between active and placebo that is not real or relevant, resulting in marketing of a drug that performs inadequately and thereby adversely affects public health. Therefore, for group trials, the statistical barrier to declare a difference is appropriately high (P<0.05). For SPTs, a larger type I error (e.g., P<0.10) may be appropriate because the greater risk is to deprive the individual patient from enjoying a measurable but modest improvement, particularly when the tested drug has already been shown to be safe and effective (on average) in the general population via group trials. 17 
■■ Limitations
Our work indicates that many GERD patients on PPIs may be converted to lower-cost treatments using SPTs, and with comparable or better outcomes. This is closely aligned with the purpose of managed care. However, the results of this trial cannot be definitively extrapolated to a managed care environment and require further validation in a setting where there are many GERD patients under management.
The observed SPT evaluable-study rate of 84% may well reflect the high level of interest patients have in understanding how to appropriately ease their pain and other undesirable symptoms. However, a limitation of the current work is that the study was conducted via investigative sites requiring several patient visits. Ideally, a commercial product would be selfexplanatory, requiring few or no patient visits and would exert no extra burden on physicians and their routine practices. We are encouraged that the surveys conducted showed that, with modest instruction, patients understood how to use the kit.
■■ Future Directions
The appropriate next step for product evaluation would be a formal "test market," where test kits are dispensed by prescription directly to patients. Compliance would be monitored and reporting managed by a sophisticated and dedicated, pharmacy-based, medication therapy management operation rather than an investigational site. Patients would be followed to determine how many patients remained on a treatment based on study results, and their outcomes would be documented.
Pharmacogenomic technologies may also provide "personalized medicine" solutions in the future, although many years may be required to adequately validate the methods. These opportunities have been widely anticipated by the medical, financial, and lay press in recent years. 24 It may, at some point, be reasonable to incorporate pharmacogenomic markers into SPTs as primary effectiveness and/or safety endpoints. The combined "personalization" technologies may serve to generate superior prognostic assessments compared to each used independently.
If routinely used, the validated SPT kit for GERD is anticipated to have an important impact on patient outcomes, satisfaction with health care, and public health. Moreover, the power of the current method to discriminate individual patient effectiveness and safety differences (and to permit full predictive use of concomitant prognostic information) can be expected to increase substantially as the database from similar patients enlarges and segmentation into population subgroups becomes feasible. This can permit more substantial adjustments between the population estimates and the individual patient' s observed results. The enlarging database could permit an even more discriminating, userfriendly, continuously improving test kit design requiring fewer questions, fewer crossover periods, and shorter study durations, resulting in greater patient compliance. 9, 10 The authors are developing additional SPTs for other chronic diseases, including allergic rhinitis 17 and osteoarthritis.
■■ Conclusion
Using SPTs, high rates of evidence-based, step-down/discontinuation from unnecessary drugs can be achieved. The SPT kit was judged useful and feasible to administer by patients. It can statistically discriminate effectiveness and adverse events and may serve as a useful tool in community practice, improving outcomes by determining the least costly, evidence-appropriate treatment. When omeprazole becomes available as an inexpensive generic drug, the step-down rate for therapeutic substitution from a new-generation proton pump inhibitor to another biologically similar PPI can be substantially greater than that observed for ranitidine, a histamine-2 receptor antagonist.
